Global Breast Cancer Drugs Market 2021 (Includes Business Impact of COVID-19)

  • TBI247987
  • September 16, 2021
  • Global
  • 149 pages
  • Market.US
                                              

Report updated on 11th September, 2021: Global Breast Cancer Drugs Market 2021 (Includes Business Impact of COVID-19)

Global Breast Cancer Drugs Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2030 is a recent report generated by Trusted Business Insights. The global breast cancer drugs market report has been segmented on the basis of product type, technology and region. Request Covid - 19 Impact

Global Breast Cancer Drugs Market: Overview

Breast cancer is a type of cancer, that can occur more in women than in men. Some of the symptoms of the disease include bloody secretion from the nipple, a lump or block in the breast, and differences in the texture or shape of the nipple or breast. The treatment of breast cancer is depending on the stage of cancer. In addition, its treatment can consist of radiation, hormone therapy, chemotherapy, and surgery. Early detection of breast cancer is key to effective treatment of the disease. Also, early exposure of disease can lead to better outcomes including a number of treatment options, improved survival rate, and changed quality of life. There exist a rising pressure and demand for novel therapies or treatment owing to the rapidly growing prevalence of diseases. The strong pipeline is projected to provide effective and new treatment options and upgraded outcomes than already existing therapies.

Global Breast Cancer Drugs Market: Dynamics

The growing prevalence of the disease coupled with emerging and better novel therapies are some factors likely to fuel the global market growth. Global breast cancer drugs market is estimated to grow lucratively attributable to many major players are focusing on Research & Development of new and innovative treatments. They involve extensive research in order to develop novel drugs for the treatment of this disease to gain a higher market share. Various target and specific therapies have been designed and customized along with various advancements in drug delivery systems. However, aging is taken as one of the extreme risk factors for breast cancer. In addition, according to Cancer Treatment Centers of America, most women of age above 60 years are more likely to be diagnosed with cancer, whereas only around 10% to 15% of cancer cases occur in women of age 45 or less than 45 years. High prevalence of this disease along with patent expiry are some other factors that are influencing government and private investment in research and development activities of new products.

Global Breast Cancer Drugs Market: Segment Analysis

The HER2 inhibitors segment is expected as the most lucrative segment of the global market. The rising incidence of HER2 positive breast cancer is the major reason behind the growth of this segment. Furthermore, the CDK 4/6 inhibitor segment is projected to grow at the fastest rate of growth during the forecast period. The aforesaid drugs are anticipated to increase the survival rate of patients suffered from metastatic breast cancer. Additionally, advancement and innovation of novel drugs, such as Verzenio launched by Eli Lilly and Company and Kisqali launched by Novartis AG and is estimated to drive growth of this segment in the upcoming years.

Global Breast Cancer Drugs Market: Regional Analysis

Rising awareness and high presence of established players coupled with R&D infrastructure are some factors that are contributing to the high growth of the North America Market. On the other hand, the Asia Pacific market is anticipated to witness the fastest CAGR over the forecast years. The rapid growth in the global demand for oncology drugs has prompted major drug providers and manufacturers to set up their manufacturing and R&D facilities in this region. Additionally, initiatives taken by numerous organizations in order to create people more aware and raise funds for the treatment of disease is projected to feed the regional market growth.

Global Breast Cancer Drugs Market Segmentation:

Segmentation by Drug Type:
  • HER2 inhibitor
  • Mitotic inhibitor
  • Anti-metabolites
  • Aromatase inhibitor
  • CDK 4/6 inhibitor
  • Hormonal receptor

Key Market Players included in the report:

  • Abbott
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • AstraZeneca
  • BioNumerik Pharmaceuticals Inc.
  • Bristol-Myers Squibb Company.
  • Celgene Corporation
  • Celldex Therapeutics
  • Eisai Co.Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genzyme Corporation
  • GlaxoSmithKline plc.
  • Janssen Global services LLC
  • Johnson & Johnson Services Group.
  • MacroGenics Inc.
  • Merck & Co.Inc.
  • Mylan N.V
  • Novartis AG
  • Onyx Pharmaceuticals Inc.
  • PfizerInc.
  • Sanofi
  • Takeda Pharmaceutical Company Limited.
  • Teva Pharmaceutical Industries Ltd.

Below are the key development related to Breast Cancer Drugs Market in 2020 and 2021.

May 2021: GE Healthcare Acquires Zionexa; Molecular Imaging Agent Aims to Enable More Targeted Treatment for Metastatic Breast Cancer Patients. GE Healthcare announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna™ (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer. Source February 2021: Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market. Breast Cancer Index™ Added to National Comprehensive Cancer Network Guidelines to Predict Benefit from Extended Endocrine Therapy. Hologic, Inc. (Nasdaq: HOLX), a global leader in womens health, has completed its previously announced acquisition of molecular oncology leader Biotheranostics, Inc. for approximately $230 million. Biotheranostics develops and markets two highly differentiated molecular diagnostic tests for breast and metastatic cancers – Breast Cancer Index™ (BCI) and CancerTYPE ID® (CTID). Source November 2020: Merck & Co. to Acquire VelosBio for $2.75B, Expanding Cancer Pipeline. Merck & Co. has agreed to acquire VelosBio for $2.75 billion cash, the companies said, in a deal that bolsters the buyer’s growing oncology pipeline with a clinical-phase antibody-drug conjugate being evaluated for solid tumors and blood-based cancers. Based in San Diego, privately-held VelosBio last month dosed its first patient in a Phase II trial (NCT04504916) of VLS-101, designed to evaluate the ADC in patients with solid tumors that include triple-negative breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer, and non-squamous non-small-cell lung cancer (NSCLC). Source September 2020: Gilead to Acquire Immunomedics for $21B, Adding Breast Cancer ADC to Oncology Portfolio. Gilead Sciences said it has agreed to acquire Immunomedics for approximately $21 billion, in a blockbuster deal designed to bolster the buyer’s oncology portfolio with a first-in-class breast cancer treatment that won FDA accelerated approval in April. The acquisition will bring to Gilead TrodelvyTM (sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) indicated for the treatment of adults with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Trodelvy was launched in May of 2020 and according to Gilead has significant commercial potential in mTNBC and other solid tumors. Source

Table of Contents
Chapter 1. Methodology and Scope                  1.1. Research Methodology                  1.2. Research Scope & Assumptions                  1.3. List of Data SourcesChapter 2. Executive SummaryChapter 3. Global Breast Cancer Drugs Market Outlook                  3.1. Market Segmentation                  3.2. Market Size and Growth Prospects, 2016 - 2027                  3.3. Value Chain Analysis                  3.4. Market Dynamics                      3.4.1. Market driver analysis                      3.4.2. Market restraint analysis        
|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form